Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification

Eur Urol. 2023 Apr;83(4):301-303. doi: 10.1016/j.eururo.2022.09.015. Epub 2022 Oct 4.


We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.

Publication types

  • Editorial

MeSH terms

  • Adenocarcinoma* / pathology
  • Humans
  • Male
  • Neoplasm Grading
  • Prostate / pathology
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / pathology


  • Prostate-Specific Antigen